Related by context. All words. (Click for frequent words.) 82 8mg/kg 78 achieved ACR# 76 oxycodone CR 75 4mg/kg 75 ACTEMRA TM 75 plus MTX 75 mcg BID 75 #mg BID [001] 75 lopinavir r arm 74 mg QD 73 CIMZIA TM 73 receiving golimumab 73 mcg QD 73 mg ustekinumab 72 placebo dexamethasone 72 dapagliflozin plus 72 mg BID 72 adjunctive placebo 72 adalimumab 71 certolizumab 71 mitoxantrone plus 71 adalimumab Humira 71 ACR# response 71 methotrexate monotherapy 71 MCyR 71 budesonide pMDI 71 mcg kg REBETOL 71 REYATAZ r arm 71 ACTEMRA 70 LEXIVA r 70 q#h 70 alfa 2a 70 tolterodine ER 70 #mg/day [002] 70 receiving PEGINTRON 70 saline placebo 70 Zometa hazard 70 PASI scores 70 clodronate 70 ritonavir boosted 70 BARACLUDE ® 70 plus prednisone prednisolone 70 HBeAg seroconversion 69 #mg/m# [001] 69 Psoriasis Area 69 desvenlafaxine succinate 69 Flu Cy 69 mg TID 69 IFN alfa 69 APTIVUS r 69 golimumab CNTO 69 plus dexamethasone 69 HBeAg negative patients 69 achieved PASI 69 FluCAM arm 69 CIMZIA TM certolizumab pegol 69 FOLPI 69 Pegasys ® 69 seropositive patients 69 bleeding pallor 69 peginterferon alfa 2a 69 placebo p = 69 Peg IFN 69 CCyR 69 lopinavir r 69 mcg albinterferon alfa 2b 69 autoantibody positive 69 CIMZIA ™ 68 tapentadol ER 68 relapsed MM 68 mg/m2 IV 68 PREZISTA r 68 TMC# r 68 nadolol 68 discontinuations due 68 PsA 68 weekly subcutaneous injections 68 sUA 68 mcg Albuferon 68 comparator arm 68 infliximab monotherapy 68 certolizumab pegol 68 REMICADE monotherapy 68 active comparator 68 receiving VICTRELIS 68 humanized interleukin 6 68 methotrexate MTX 68 #mg BID [003] 68 rosuvastatin #mg 68 teriflunomide 68 achieved CCyR 68 octreotide LAR 68 FOLFOX4 alone 68 transaminase elevations 68 chlorambucil 68 ULORIC 68 #mg QD [002] 68 tocilizumab 68 lumbar spine BMD 68 adefovir 68 Acetate Rectal Suppositories 68 atazanavir ritonavir 68 etanercept 68 ACR# responses 67 PREZISTA ritonavir 67 #mg/day [001] 67 oral allopurinol 67 HBeAg positive patients 67 tipranavir r 67 adjunctive ABILIFY 67 MADRS score 67 plus prednisone 67 mcg kg 67 headache nasopharyngitis 67 splenectomized 67 FluCAM 67 receiving XGEVA 67 Crohn Disease Activity 67 Index CDAI 67 achieved statistical significance 67 3mg/kg 67 receiving VELCADE 67 QTcF 67 morphometric vertebral fractures 67 FOLFOX4 67 ALVESCO 67 HBeAg negative 67 clinically meaningful improvement 67 prednisone prednisolone plus 67 plus gemcitabine 67 mg kg dose 67 mitoxantrone 67 AGILECT R 67 lamivudine refractory patients 67 salmeterol fluticasone 67 moderate renal impairment 67 -#.# mg dL [002] 67 mg qd 67 plus OBT 67 severe exacerbations 67 doxorubicin cyclophosphamide 67 irbesartan 67 REMICADE ® 67 liver histology 67 mg Lucentis 67 zolmitriptan 67 interferon ribavirin 67 Adalimumab 67 TEAEs 67 receiving INTRON 67 μg dose 67 leukemia AML 67 non splenectomized 66 dalteparin 66 clinically meaningful improvements 66 RLAI 66 active ankylosing spondylitis 66 ascending dose 66 DAS# CRP 66 plus COPEGUS 66 Betaferon R 66 PREZISTA r arm 66 interferon alfa 2b 66 fatigue asthenia 66 placebo p 66 Engerix B 66 PEGylated anti 66 interferon alfa 2a 66 hyperphenylalaninemia HPA due 66 biologic DMARD 66 cytogenetic response 66 alanine aminotransferase 66 #mg doses [002] 66 oral antidiabetic medication 66 Oral Fingolimod 66 peginterferon alfa 2a Pegasys 66 sustained virologic response 66 benazepril 66 evaluable subjects 66 somatostatin analog 66 mg subcutaneously 66 EDSS scores 66 fluticasone salmeterol 66 mg kg belimumab 66 evaluating tivozanib 66 Kinoid 66 generalized edema 66 #mg QD [001] 66 laboratory abnormalities 66 Doxil ® 66 solifenacin 66 nicardipine 66 PRADAXA #mg 66 APTIVUS R 66 receiving ISENTRESS 66 oral diclofenac 66 log# IU mL 66 complete cytogenetic response 66 stage IIIb IV 66 CHOP chemotherapy 66 venlafaxine XR 66 receiving highly emetogenic 66 Naive Patients 66 psoriatic arthritis PsA 66 Durezol 66 estramustine 66 mg/m2 dose 66 FOLFOX 66 anthracycline taxane 66 FUSILEV enhances 66 anemia hemoglobin 66 Pegasys plus Copegus 66 urate lowering therapy 66 Q2W 66 baminercept 66 alanine aminotransferase ALT 66 partial remissions 66 aminotransferase elevations greater 66 CR nPR 66 amprenavir 66 mucosal healing 66 ribavirin RBV 66 Aptivus ® 66 pyridostigmine 66 hematologic toxicity 66 #.#/#.# mmHg [001] 65 corticosteroid dose 65 biochemical relapse 65 recurrent glioblastoma multiforme 65 mg/m2 administered 65 progressive PsA 65 daunorubicin 65 baseline HbA1c 65 RoACTEMRA 65 aspartate aminotransferase 65 Infusion Reactions Severe 65 ATACAND 65 FOLFOX6 65 radiographic progression 65 administered subcutaneously 65 hypophosphatemia 65 serologically active patients 65 Newly Diagnosed Multiple Myeloma 65 Pharmacokinetics PK 65 elevated ALT 65 HBeAg positive 65 GOUT 65 colesevelam HCl 65 PROCTOCORT ® Suppository Hydrocortisone 65 mcg doses 65 AZT zidovudine Retrovir 65 receiving SIMPONI 65 carboplatin paclitaxel 65 Peginterferon 65 RRMS patients 65 PEGylated Fab fragment 65 RAPTIVA 65 LEXIVA 65 gemcitabine carboplatin 65 rimonabant #mg 65 receiving prophylactic anticoagulation 65 PEG Intron 65 lymphopenia 65 oxycodone IR 65 log# reduction 65 Scale EDSS 65 #.#mg/dL 65 oral rivaroxaban 65 abacavir lamivudine 65 paclitaxel cisplatin 65 R# #mg BID 65 serum urate 65 Ishak fibrosis score 65 mg simvastatin 65 REYATAZ r 65 ribavirin therapy 65 Severity Index PASI 65 ribavirin USP 65 virologic breakthrough 65 mg dose 65 antiretroviral naïve 65 azathioprine 65 #mg/m# [002] 65 rimonabant #mg/day 65 FOLFIRI alone 65 ibandronate 65 TO AVOID PREGNANCY WHILE 65 Postoperatively 65 bortezomib refractory 65 STELARA ® 65 zonisamide SR 65 acromegalic patients 65 neutropaenia 65 5-FU/LV 65 spontaneous bowel movements 65 nadroparin 65 inhalations twice 65 titrated glipizide 65 Cutaneous T 65 VELCADE melphalan 65 sulfasalazine 65 QD dosing 65 primary hypercholesterolemia 65 adriamycin 65 mild renal insufficiency 65 hypomagnesemia 65 doxazosin 65 ARCALYST ® 65 antiretroviral naive 65 q8h 65 gout flares 65 pegylated interferon alfa 2a 65 vitreous floaters 65 Folfox 65 R adalimumab 64 enalapril 64 nucleoside naive 64 arthritis PsA 64 undetectable HBV DNA 64 plasma HCV RNA 64 Juvenile Idiopathic Arthritis 64 fasting plasma glucose FPG 64 -#.# mg dL [001] 64 peripheral sensory neuropathy 64 piperacillin tazobactam 64 cyclophosphamide doxorubicin vincristine 64 FFNS 64 daily Infergen 64 hour bronchodilation 64 Abbott HUMIRA 64 linaclotide treated 64 dosing cohorts 64 alemtuzumab treated 64 SGPT 64 weekly CSBMs 64 paliperidone ER 64 pegylated interferon alpha 64 adefovir treated 64 elevated serum creatinine 64 azilsartan medoxomil 64 Pred Forte 64 metastatic GIST 64 bone marrow reticulin deposition 64 Primary endpoints 64 HCV RESPOND 2 64 5mg/kg 64 TDF FTC 64 steroid dexamethasone 64 #mg dose [002] 64 Peginterferon Alfa 2a 64 unresectable HCC 64 subcutaneous enoxaparin 64 ACR# [002] 64 quetiapine XR 64 INTEGRILIN R 64 pruritus itching 64 cyclophosphamide chemotherapy 64 KRAS mutations occur 64 oral FTY# 64 darunavir r 64 cytogenetic responses 64 FOLFIRI 64 Platinol ® cisplatin 64 dose cytarabine 64 pamidronate 64 tamsulosin 64 Patients Receiving 64 sumatriptan naproxen sodium 64 diarrhea nausea fatigue 64 insulin glulisine 64 Traficet EN 64 lenalidomide dexamethasone 64 mycophenolate mofetil 64 ritonavir boosted atazanavir 64 INCB# [003] 64 eosinophilic asthma 64 severe neutropenia 64 R adefovir dipivoxil 64 insulin detemir 64 Apidra ® 64 forodesine 64 dizziness nausea diarrhea 64 naïve HCV 64 imipenem 64 neutropenia dehydration dyspnea 64 Relapsing Multiple Sclerosis 64 peg IFN 64 ACR# ACR# 64 complete cytogenetic 64 Relapsed Multiple Myeloma 64 serum phosphorous 64 Free Survival PFS 64 Viread Emtriva 64 treatment naïve genotype 64 REYATAZ ritonavir 64 LPV r 64 KRAS mutant tumors 64 baseline PASI 64 severely active polyarticular 64 Fludara 64 flutamide 64 % CI #.#-#.# [003] 64 tirofiban 64 DAS# remission 64 low dose Iluvien 64 LymphoStat B belimumab 64 Disease Activity 64 PROMACTA 64 MACUGEN 64 bupropion SR 64 SPRYCEL ® 64 Golimumab 64 Refractory Hodgkin Lymphoma 64 anakinra 64 FOLPI regimen 64 PEGINTRON TM 64 intravascular hemolysis 64 pegylated liposomal doxorubicin 64 peginterferon alfa 2b 64 interferon alfa 64 splenectomized patients 64 lumbar spine bone 64 Cimzia TM 64 receiving immunosuppressive therapy 64 Lucentis monotherapy 64 glycated hemoglobin levels 64 events SAEs 64 ALT flares 64 pegIFN 64 galiximab 64 ALT normalization 64 incidence ≥ 64 Adefovir 64 timepoints 64 experienced virologic failure 63 plus ribavirin 63 HAM D# scores 63 statin monotherapy 63 #mg #mg #mg [003] 63 ropivacaine 63 haematologic 63 Etanercept 63 TNF Tumor Necrosis Factor 63 canakinumab 63 tolvaptan 63 placebo 63 Castration Resistant Prostate Cancer 63 amoxicillin clavulanate 63 annualized relapse 63 intravitreal injections 63 ACE Inhibitors 63 low dose cytarabine 63 TAXOTERE R 63 nab paclitaxel 63 tenofovir emtricitabine 63 headache abdominal pain 63 novel VDA molecule 63 PegIFN RBV 63 pegylated interferon peg IFN 63 echinacea tablets 63 deep venous thromboses 63 mapatumumab 63 log# copies mL 63 intraocular inflammation 63 BoNTA 63 undetectable viral 63 microbiological eradication 63 tipranavir ritonavir 63 Expanded Disability Status 63 mg kg REMICADE 63 pyrexia mucositis sepsis febrile 63 Pegasys peginterferon alfa 2a 63 KAPIDEX 63 pegylated interferon alfa 63 DOXIL 63 CYT# potent vascular disrupting 63 Index CDAI score 63 hepatitis C genotype 63 #μg [002] 63 DMARD therapy 63 azathioprine monotherapy 63 imatinib therapy 63 mg RDEA# 63 Inventory BPI 63 CYPHER Stent 63 UPDRS motor 63 Natalizumab 63 lenalidomide Revlimid R 63 peg interferon 63 leukopenia 63 heavily pretreated patients 63 conjunctival hyperemia 63 lispro 63 Median PFS 63 #mg q8h 63 rapid virologic response 63 TNF antagonist 63 corticosteroid therapy 63 Raptiva r 63 mGluR5 NAM 63 mg Proellex 63 relapsed refractory multiple myeloma 63 chills fever headache 63 HBeAg + 63 neurologic progression 63 metformin monotherapy 63 TOVIAZ 63 somnolence dizziness 63 mg eq 63 CR CRu 63 EUFLEXXA R 63 highly emetogenic 63 response CCyR 63 Lupuzor ™ 63 DAS# [002] 63 timepoint 63 Myelodysplastic Syndrome MDS 63 patients evaluable 63 neutropenic sepsis 63 Crohn disease CD 63 DMARD 63 overt nephropathy 63 febrile neutropenia 63 pyrazinamide 63 candesartan cilexetil 63 Score DAS 63 tapentadol IR 63 events AEs 63 HMG CoA reductase inhibitor 63 postmenopausal osteoporotic women 63 GERD symptom 63 transaminases 63 brand ciclesonide HFA 63 treatment naive genotype 63 esomeprazole 63 aspartate aminotransferase AST 63 Meets Primary Endpoint 63 dermatologic toxicities 63 paricalcitol 63 AVONEX ® 63 Cimzia ® certolizumab pegol 63 intravenous bolus 63 telaprevir dosed 63 ACZ# 63 mg administered orally 63 apremilast 63 dacarbazine 63 sorafenib tablets 63 protease inhibitor PI 63 atorvastatin #mg 63 atazanavir sulfate 63 aplastic anemia AA 63 serum phosphate 63 decitabine 63 squamous histology 63 MIRAPEX 63 ankylosing spondylitis AS 63 mg doses 63 odanacatib 63 biphasic insulin aspart 63 post herpetic neuralgia PHN 63 Complicated Skin 63 nonsignificant difference 63 interferon beta therapy 63 SGOT 63 mg BID dose 63 achieving PASI 63 mg tid 63 Relapsed Refractory 63 achieved sustained virologic 63 icatibant 63 Cream USP 1 63 idiopathic Parkinson disease 63 ADCS CGIC 63 Lantus ® 63 CLINICAL STUDIES 63 inactive placebo 63 ecchymosis 63 abatacept 63 #mg dose [001] 63 Relapsing Remitting Multiple Sclerosis 63 titrated glipizide plus 63 NATRECOR R 63 LANTUS R 63 seroprotection 63 sustained virological response 63 sUA levels 63 Solid Tumors criteria 63 tamoxifen Nolvadex ® 63 Peginterferon alfa 2b 63 mg Pycnogenol 63 x ULN 62 Cimzia ® 62 YMRS 62 Ribavirin causes 62 peginterferon 62 CsA 62 #mg dose [003] 62 CTAP# Capsules 62 Tarceva TM 62 anterior uveitis 62 dose cohort 62 Thal Dex 62 Median progression 62 tiotropium 62 azacytidine 62 mg/# hr 62 MACCE 62 nonvertebral fractures 62 mcg dose 62 intravenous vancomycin 62 ALIMTA cisplatin 62 melphalan prednisone 62 -#.# log# copies mL 62 alfuzosin 62 venlafaxine Effexor 62 mg hydrochlorothiazide 62 conventional DMARDs 62 PLX STROKE targeting 62 elevated lipase 62 ug dose 62 visilizumab 62 CLL SLL 62 baseline A1C 62 ruboxistaurin 62 Fibromyalgia Impact Questionnaire 62 genotype 1b 62 elevated transaminases 62 relapsing multiple sclerosis 62 MYCAMINE 62 Teriflunomide 62 Adjunctive Therapy 62 TNF receptor 62 Mg Uk 62 recurrent genital herpes 62 SCIg 62 briakinumab 62 myelodysplastic myeloproliferative diseases 62 Mg Usa 62 weekly intravenous infusions 62 nephrotoxicity 62 MoxDuo TM IR 62 fluticasone 62 Ceplene/IL-2 62 DMARDs 62 mg subcutaneous 62 hypokalemia 62 fosamprenavir 62 prior chemotherapy regimens 62 #ug [001] 62 docetaxel Taxotere ® 62 asthenia fatigue 62 Treatment Naive Patients 62 NPH insulin 62 ara C 62 dosing cohort 62 mg q#h 62 cabazitaxel 62 nondiabetic patients 62 dasatinib Sprycel ® 62 febuxostat 62 achieved mucosal healing 62 calculated creatinine clearance 62 randomized #:#:# 62 TAXUS p value 62 #mg/kg [002] 62 superficial edema 62 IOP lowering 62 refractory cutaneous T 62 leucopenia 62 continuous intravenous infusion 62 Aflibercept 62 fluticasone furoate 62 dexamethasone Decadron 62 cyclophosphamide Cytoxan 62 peginterferon alfa 62 cisplatin vinorelbine 62 Montgomery Asberg Depression 62 P = .# 62 sensory neuropathy 62 pegaptanib 62 infliximab 62 mg m² 62 blood Phe levels 62 H2RAs 62 mesalamine granules 62 ABC/3TC 62 C1 INH deficiency 62 KOMBIGLYZE XR 62 subcutaneous doses 62 neutropenia thrombocytopenia 62 PREZISTA rtv 62 fluticasone propionate 62 CIMZIA R 62 azacitidine 62 hip BMD 62 intra articular injection 62 virologic suppression 62 olmesartan 62 PSA nadir 62 neutropenia fatigue 62 RAPAFLO R 62 hypertrichosis occurred 62 indinavir 62 Viread Emtriva Sustiva 62 APTIVUS 62 median PFS 62 TPV r 62 epoetin beta 62 fluvastatin 62 Pegylated Interferon 62 Lubiprostone 62 teriparatide 62 basal bolus regimen 62 serum urate levels 62 ARCOXIA 62 COMBIVIR 62 posaconazole 62 Treated Patients 62 PEG IFN 62 methotrexate 62 rFVIIa 62 mg/m2/day 62 CANCIDAS 62 mg dosed twice 62 daily subcutaneous injections 62 PEGASYS ® 62 metformin sulfonylurea 62 antibody MAb 62 Erythropoietic therapies may 62 virologic response 62 Tolerability 62 cisplatin gemcitabine 62 AGILECT ® 62 aminotransferases 62 Navelbine 62 Elitek 62 rizatriptan 62 de novo kidney transplant 62 gemcitabine cisplatin 62 PEGylated interferon beta 1a 62 -#.# log# 62 metastatic malignant 62 binary restenosis 62 cyclophosphamide methotrexate 62 REYATAZ R 62 valsartan amlodipine 62 subcutaneously administered 62 avosentan 62 Pemetrexed 62 standard chemotherapy regimen 62 STELARA 62 ® lenalidomide 62 PRN FDA Approves 62 non menstrual pelvic 62 chronic eosinophilic leukemia 62 alicaforsen enema 62 zoledronate 62 intravenous bisphosphonates 62 Telithromycin 62 refractory NSCLC 62 % CI #.#-#.# [007] 62 VIIBRYD 62 cis retinoic acid 62 HIV HCV coinfected 62 Tocilizumab 62 Tipranavir 62 stage IIIB 62 log# 62 ZOLINZA 62 FOSRENOL ® 62 demonstrated clinically meaningful 62 postdose 62 sham injections 62 rheumatoid arthritis RA psoriatic 62 oral vancomycin 62 heavily pretreated 62 hemoglobin A1c levels 62 Antitumor Activity 62 idarubicin 62 Decitabine 62 oral levofloxacin 62 HDRS 62 placebo fluoxetine 62 crizotinib PF # 62 hours postdose 62 pioglitazone HCl 62 PEG Interferon alfa 62 mCi kg 62 sunitinib Sutent ® 62 STELARA ™ 62 docetaxel chemotherapy 62 Nilotinib 62 placebo PBO 62 p = NS 62 lamivudine monotherapy 62 BARACLUDE r 62 glyburide 62 oral clodronate 62 HBeAg 62 ORENCIA ® 62 #mg dosing 62 clinically meaningful reductions 62 refractory chronic lymphocytic 62 diarrhea nausea vomiting 62 degarelix 62 ceftazidime 61 bosentan 61 bisoprolol 61 recurrent malignant glioma 61 BENICAR HCT 61 NovoLog ® Mix 61 HGS ETR1 mapatumumab 61 myocardial infarction ventricular fibrillation 61 COPAXONE R 61 Pivotal Phase III 61 AVODART 61 prednisone prednisolone 61 oblimersen 61 vWF 61 complete remissions 61 Rating Scale MADRS 61 SJIA 61 huN# DM1 61 oral hypoglycemic agent 61 XIENCE V PROMUS Stent 61 peginterferon alfa 2a #KD 61 undetectable HCV RNA 61 Lamictal XR 61 tiotropium bromide 61 postoperatively 61 arterial thromboembolic events 61 FEMALES SHOULD BE ADVISED 61 alpha 2a 61 3TC lamivudine Epivir 61 salmeterol inhalation powder 61 adefovir dipivoxil 61 HAQ DI 61 + PH# 61 Patients Treated 61 steroid refractory ulcerative 61 CDAI 61 R entecavir 61 Ophena TM 61 ACR Pedi 61 hepatic enzymes 61 ascending doses 61 ejection fractions 61 polyneuropathy HIV DSP 61 OADs 61 mg d 61 potent CYP#A# inhibitors 61 intermittent dosing 61 #.#g/day 61 glimepiride 61 nasopharyngitis headache 61 NMIBC 61 entecavir 61 subcutaneous injections 61 Copegus ribavirin 61 rotigotine 61 peginterferon alpha 2a 61 DMARDS 61 serologically active SLE 61 nasopharyngitis 61 idraparinux 61 doxorubicin docetaxel 61 peginterferon ribavirin 61 retinal vein occlusion 61 ulcerative colitis Crohn disease 61 sunitinib Sutent 61 serum HBV DNA 61 Abrupt discontinuation 61 constipation nausea 61 Linagliptin 61 CK # plasma concentrations 61 somnolence fatigue 61 partial onset seizures 61 SSRI SNRI 61 systemic corticosteroid 61 Is Well Tolerated 61 Prolongs Survival 61 subcutaneous dose 61 deferoxamine 61 null responder HCV 61 INFERGEN 61 pomalidomide 61 ARB telmisartan 61 REYATAZ ® 61 primary generalized tonic 61 unfractionated heparin UFH 61 blastic phase 61 postoperative inflammation 61 IFN α 61 inflammatory lesions 61 Hypertensive adverse reactions 61 aminotransferase ALT 61 relapsed CLL 61 mutated KRAS 61 refractory gout 61 arthralgias 61 CRp 61 cerebrovascular events 61 β blockers 61 ethambutol 61 cilostazol 61 injected subcutaneously 61 palifermin 61 primidone 61 del 5q MDS 61 DAS# scores 61 valacyclovir 61 Phase 2b Clinical Trial 61 decompensated liver disease 61 glatiramer acetate 61 Autologous Stem Cell Transplantation 61 neutrophil counts 61 Stomatitis 61 locoregional disease 61 virologically suppressed 61 ELOXATIN 61 Hormone Refractory Prostate Cancer 61 relapsed myeloma 61 Monotherapy 61 pegylated interferon alfa 2b 61 Chronic Hepatitis C 61 diabetic neuropathic pain 61 r hGH 61 tacrolimus ointment 61 angiotensin receptor blocker ARB 61 reduce serum phosphate 61 virological response 61 symptomatic VTE 61 dosed orally 61 prucalopride 61 aripiprazole Abilify 61 gastrointestinal perforation 61 mCRC acneform rash 61 Platinol ® 61 ZP PTH 61 AZILECT 61 COZAAR 61 reactogenicity 61 evaluable patients 61 IELT 61 paresthesias 61 By JENNIFER LEARN 61 IBS C 61 INVEGA ® 61 HIV RNA 61 remission CR 61 angiotensin converting enzyme inhibitor 61 cisplatin chemotherapy 61 Hepsera 61 cinacalcet 61 normal ULN 61 trough FEV1 61 salmeterol fluticasone propionate 61 vincristine doxorubicin 61 thrombocytopenic 61 rituximab refractory 61 urate lowering 61 HMG CoA reductase inhibitors 61 RGT arm 61 Relapsed Refractory Multiple Myeloma 61 EDARBI 61 Interferon beta 1b 61 infliximab therapy 61 mdx mice 61 Kepivance 61 chemoradiation therapy 61 CI -#.# 61 mg/# h 61 clopidogrel Plavix 61 angioneurotic edema 61 TORISEL 61 dose cohorts 61 baseline LDH 61 DAPT 61 Secondary endpoints included 61 efavirenz EFV 61 hypercalcemia 61 MabThera Rituxan 61 Hematologic 61 esophageal candidiasis 61 sirolimus eluting stent 61 Pegylated Liposomal Doxorubicin 61 fibrinolysis 61 dasatinib Sprycel 61 Lamotrigine 61 oral prodrug 61 CRESTOR #mg 61 prulifloxacin 61 PANSS scores 61 BENICAR 61 #Gy 61 â ‰ ¥ 61 triamcinolone 61 sitaxsentan